Located at the heart of Europe’s leading life sciences cluster, Switzerland Innovation Park Basel Area offers the ideal environment for engineers, scientists, research groups, spin-offs and start-ups in the fields of precision medicine, health-oriented life sciences and biomedical engineering.
Park Basel Area contributes to the future success of its residents in three regards. To facilitate knowledge exchange and growth, Park Basel Area grants residents access to a network of academia, research institutions, industry leaders and possible investors. A target-oriented scope of services helps residents to grow their business while staying focused on turning their ideas into marketable products. The Park Basel Area facilities comprise 6,000 square meters of private and shared workspace, including turn-key labs and well-equipped infrastructure, fostering teamwork and collaboration.
«A community to nurture your innovations and the space to bring them to life.»
The following research groups and companies are residents at Switzerland Innovation Park Basel Area:
Ad Mirabiles AG: Patient specific implants for any type of indication, focusing in particular on CMF applications and PEEK implants
Algae Natural Switzerland AG: Provide protein and/or omega 3 rich high quality micro-algae for food and feed applications – the production process for organic micro algae production is developed based on a sustainable and circular approach for a successful eco-conception
Alibion GmbH: Alibion is a biotech company focused on accelerating the development of therapeutics through early stages.
Captor Therapeutics: Polish biotech company developing drug candidates for the treatment of oncology and chronic inflammation.
Catalyze: Catalyze helps researchers and companies secure financing for ambitious R&D projects, from early stage pre-clinical research up to clinical stage development.
Department of Biomedical Engineering (DBE), University of Basel: Ten research groups with the subsequent focal areas: Biomechanics and biomaterials, computational modelling, imaging and image analysis, laser and robotics, regenerative medicine
Di Meliora SA: New dental implant designs that aim to solve challenges like marginal bone loss, implant cleaning, bone augmentation
GPRS – Gombert Pharma Research Solutions: Offers consultancy and services for pharmaceutical research. Our aim is to support our clients in all aspects of identifying new targets, drug candidates and therapies through drug discovery and early clinical development phases.
Peter Kelly Pharma: Drug-discovery, specializing in diseases of the nervous system, such as Alzheimer’s Disease (AD)
Predemtec AG: Research, development and manufacturing of innovative diagnostic tests for the diagnosis of risk factors of dementias
Polyneuron AG: Development of a promising new drug class to treat autoimmune disorders
Q-Linked AG: We consult, support and accompany enterprises during an envisaged ISO certification and provide high quality assistance during staffing bottleneck. We strive for intelligible and useful solutions and are able to provide, thanks to our contemporary understanding of Quality Management, a practice-oriented management and early-warning system.
SunRegen Healthcare AG: SunRegen is a biopharmaceutical company focusing on developing innovative treatments for patients with neurodegenerative diseases.
Spheroidals AG: Spin-off from the University Hospital Basel. This company devotes itself to developing novel nanotechnologies in medical application, mainly focusing on non-invasive imaging of atherosclerosis and targeted anti-atherosclerosis therapy.
Switzerland Innovation Park Basel Area congratulates our alumni companies:
Skyhawk Therapeutics Inc.: Drug discovery company with a novel platform to develop small molecules targeting RNA
Versameb AG: Research and development in the field of regenerative medicine, looking to design novel technologies